Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The National Cerebral And Cardiovascular Center is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, which means that every active matter is being reviewed by a different official. This lack of examiner overlap suggests that the center must tailor its legal arguments to 5 unique sets of examiner preferences and communication styles.
The workload is further spread across 4 distinct art units, reflecting a broad technical scope within the biotechnology sector. MCANANY, JOHN D is identified as the busiest examiner for this portfolio, although he is responsible for only 1 pending office action. This indicates that the 5 pending office actions are shared relatively evenly across the 5 distinct examiners, with no single individual dominating the prosecution landscape.
Managing 5 pending office actions across 4 distinct art units requires a versatile approach to patent strategy. The distribution of work means that the National Cerebral And Cardiovascular Center cannot rely on a single point of contact at the USPTO. Instead, the center must navigate the specific standards of 4 different art units, which may have varying interpretations of patentability within the Biotechnology & Pharmaceuticals field, necessitating a highly adaptable prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.2% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
| LUSI, ELLIS FOLLETT | 1 | 63.5% | +53.4% |
| KIRWIN, STEFANIE JOHANNA | 1 | 15.9% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275602 | METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY | MCCOLLUM, ANDREA K | — |
| 18031919 | Method for Detecting Genetic Polymorphism | SCHLOOP, ALLISON ELIZABETH | — |
| 17043195 | NOVEL AORTIC ANEURYSM MARKER | KIRWIN, STEFANIE JOHANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17599475 | ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS-RELATED DISEASE MARKER | LUSI, ELLIS FOLLETT | 62d |
| 18275602 | METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY | MCCOLLUM, ANDREA K | — |
| 18031919 | Method for Detecting Genetic Polymorphism | SCHLOOP, ALLISON ELIZABETH | — |
| 17043195 | NOVEL AORTIC ANEURYSM MARKER | KIRWIN, STEFANIE JOHANNA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 2 |
| 1674 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275602 | METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Non-Final OA | — | Pending | Aug 02, 2023 |
| 18031919 | Method for Detecting Genetic Polymorphism | SCHLOOP, ALLISON ELIZABETH | 1683 | §103§112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17599475 | ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS-RELATED DISEASE MARKER | LUSI, ELLIS FOLLETT | 1677 | §103DPOther | Non-Final OA | 62d | Pending | Sep 28, 2021 |
| 17043195 | NOVEL AORTIC ANEURYSM MARKER | KIRWIN, STEFANIE JOHANNA | 1677 | §103§112Other | Non-Final OA | — | Pending | Nov 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial